Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update

Carisma Therapeutics, Inc. (NASDAQ:CARM) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 464,400 shares, a decline of 22.1% from the February 13th total of 596,500 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average daily trading volume, of 361,600 shares, the days-to-cover ratio is presently 1.3 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its holdings in Carisma Therapeutics by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after purchasing an additional 24,600 shares during the period. Barclays PLC increased its position in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares in the last quarter. Finally, Wexford Capital LP increased its holdings in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the period. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Stock Performance

NASDAQ:CARM opened at $0.43 on Monday. The firm’s fifty day simple moving average is $0.46 and its 200 day simple moving average is $0.71. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics has a twelve month low of $0.38 and a twelve month high of $2.66. The firm has a market capitalization of $17.74 million, a price-to-earnings ratio of -0.27 and a beta of 1.55.

Analyst Ratings Changes

A number of research firms have recently weighed in on CARM. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Carisma Therapeutics in a research note on Monday, January 13th. BTIG Research cut Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Robert W. Baird lowered shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $10.00 to $1.00 in a report on Thursday, December 12th. Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, HC Wainwright restated a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $4.94.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.